A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide 11Ms. Clineschmidt, Dr. Adamsons, Dr. Snyder, and Dr. Reines are employees of Merck &amp; Co., Inc., the manufacturer of the dorzolamide-timolol combination. The other authors have no proprietary interest in the dorzolamide-timolol combination or in Merck.

Clineschmidt, Coleen M.; Williams, R. D.; Snyder, Ellen; Adamsons, Ingrid

doi:10.1016/s0161-6420(98)91047-8

Cited by 117 publications

(31 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The incidence of treatment-related adverse events was higher in the FCDT therapy group than in the timolol monotherapy group in the Clineschmidt study and similar between groups in the Boyle study. In each study, the overall incidence of treatment-related adverse events was similar with FCDT and dorzolamide monotherapy, and the incidence of the most common side effects (ocular burning/stinging and taste perversion) was also similar with FCDT and dorzolamide alone 7,8. Interestingly, in the Clineschmidt study, the incidence of conjunctivitis was significantly lower in the FCDT group than in the dorzolamide group (0% vs 6%, P = 0.034) 8.…”

Section: Efficacy and Safety Of Fixed Combinations Compared With Compmentioning

confidence: 72%

“…In each study, the overall incidence of treatment-related adverse events was similar with FCDT and dorzolamide monotherapy, and the incidence of the most common side effects (ocular burning/stinging and taste perversion) was also similar with FCDT and dorzolamide alone 7,8. Interestingly, in the Clineschmidt study, the incidence of conjunctivitis was significantly lower in the FCDT group than in the dorzolamide group (0% vs 6%, P = 0.034) 8. It should be noted that the concentration of the preservative is the same in FCDT and dorzolamide, although exposure to preservative was greater with dorzolamide because it was dosed 3-times daily (tid) vs twice daily (bid).…”

Section: Efficacy and Safety Of Fixed Combinations Compared With Compmentioning

confidence: 82%

“…Two separate 3-month, randomized, double-masked studies reported by Boyle et al7 and Clineschmidt et al8 compared fixed-combination dorzolamide 2%/timolol 0.5% (FCDT) to monotherapy with the component medications. The Boyle study was carried out in 335 patients after washout of previous medications7 and the Clineschmidt study in 253 patients after a 3-week run-in on timolol 8.…”

Section: Efficacy and Safety Of Fixed Combinations Compared With Compmentioning

confidence: 99%

“…The Boyle study was carried out in 335 patients after washout of previous medications7 and the Clineschmidt study in 253 patients after a 3-week run-in on timolol 8. FCDT and timolol were dosed twice daily while dorzolamide was dosed thrice daily.…”

Section: Efficacy and Safety Of Fixed Combinations Compared With Compmentioning

confidence: 99%

See 3 more Smart Citations

Considerations in glaucoma therapy: fixed combinations versus their component medications

Higginbotham

2009

OPTH

View full text Add to dashboard Cite

Fixed combinations of medications that lower intraocular pressure (IOP) are increasingly used in the treatment of glaucoma and ocular hypertension and offer several potential advantages over combined use of the separate component medications including enhanced convenience, improved adherence, reduced exposure to preservatives, and possible cost savings. This review aims to examine the current role of IOP-lowering fixed combinations in disease management. The results of studies that compared the efficacy and safety of IOP-lowering fixed combinations with their component medications are summarized, including those fixed combinations that consist of a prostaglandin analog and timolol. The fixed combinations currently available for use in the United States are fixed-combination dorzolamide/timolol (FCDT) and fixed-combination brimonidine/timolol (FCBT). Both of these fixed combinations reduce IOP more effectively than their component medications used separately as monotherapy. FCBT therapy also demonstrates a more favorable safety profile and reduced ocular allergy compared to monotherapy with brimonidine, a component medication. Few studies have directly compared the efficacy and safety of FCDT and FCBT, but available evidence suggests that FCBT is at least as effective as FCDT in lowering IOP and is more comfortable and better tolerated. Additional studies are needed to further evaluate the comparative efficacy and tolerability of FCDT and FCBT in the management of glaucoma and ocular hypertension.

show abstract

Section: Efficacy and Safety Of Fixed Combinations Compared With Compmentioning

confidence: 72%

Section: Efficacy and Safety Of Fixed Combinations Compared With Compmentioning

confidence: 82%

Section: Efficacy and Safety Of Fixed Combinations Compared With Compmentioning

confidence: 99%

Section: Efficacy and Safety Of Fixed Combinations Compared With Compmentioning

confidence: 99%

See 2 more Smart Citations

Considerations in glaucoma therapy: fixed combinations versus their component medications

Higginbotham

2009

OPTH

View full text Add to dashboard Cite

show abstract

“…Not only has it been consistently reported to have a noninferiority IOP-lowering profile when compared to these agents [9,25], but it provides a preservative-free alternative in a fixed combination treatment. This may be particularly important if surgery is to be eventually considered, as long-term preservative medication could interfere with conjunctival scarring and therefore affect surgical outcomes [26].…”

Section: Discussionmentioning

confidence: 99%

Improvement in Glaucoma Patient Quality of Life by Therapy Switch to Preservative-Free Timolol/Dorzolamide Fixed Combination

Pinto

Vandewalle

Gerlier³

et al. 2013

Ophthalmologica

View full text Add to dashboard Cite

Purpose: To assess a change in visual-related quality of life (QoL) in glaucoma patients after switching from preservative-containing medical therapy to preservative-free unit dose timolol/dorzolamide fixed combination (TDFC UD). Methods: Prospective, noninterventional, multicenter 8-week study. Primary outcome was a change in visual symptoms at week 8, as assessed by the Glaucoma Symptom Scale (GSS). Results: 80 patients completed the study. There was a clinically significant increase in the scores of all GSS-related categories at week 8 when compared to baseline (GSS symptom week 8: +21.15 ± 37.9%, GSS function week 8: +10.3 ± 31.6%, both p < 0.001 vs. baseline). Comparison between patients taking only TDFC UD and patients taking TDFC UD plus concomitant medications did not detect differences in any GSS category (p > 0.50 in all comparisons). Conclusions: Switching to TDFC UD significantly improved the self-reported QoL of glaucoma patients. This can be seen even in patients who are taking concomitant ocular treatments.

show abstract

Aqueous Humor Flow in Normal Human Eyes Treated With Brimonidine and Timolol, Alone and in Combination

2001

Arch Ophthalmol

View full text Add to dashboard Cite

Cited by 117 publications

References 8 publications

Considerations in glaucoma therapy: fixed combinations versus their component medications

Considerations in glaucoma therapy: fixed combinations versus their component medications

Improvement in Glaucoma Patient Quality of Life by Therapy Switch to Preservative-Free Timolol/Dorzolamide Fixed Combination

Aqueous Humor Flow in Normal Human Eyes Treated With Brimonidine and Timolol, Alone and in Combination

Contact Info

Product

Resources

About